Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences develops and commercializes medicines for HIV, viral hepatitis, COVID-19 and cancer. Company updates regularly cover product sales and operating results, HIV franchises such as Biktarvy, Yeztugo and lenacapavir, and clinical or regulatory activity for investigational HIV regimens that combine established antiretroviral agents with newer mechanisms.
Recurring developments also include oncology pipeline expansion through Kite cell-therapy programs, the completed acquisition of Arcellx and its investigational BCMA-directed CAR T-cell therapy anitocabtagene autoleucel for multiple myeloma, collaboration activity using real-world evidence in oncology R&D, shareholder matters, and capital-structure disclosures tied to material agreements and acquisitions.
Gilead Sciences (Nasdaq: GILD) will present 13 studies at the upcoming HIV Glasgow 2020 conference, held virtually from October 5-8. These studies focus on the efficacy and safety of Biktarvy, a once-daily HIV treatment, as well as investigational long-acting therapy, lenacapavir. Gilead aims to address evolving needs in the HIV community, emphasizing patient-reported outcomes and the impact of COVID-19 on HIV care. The company is committed to scientific innovation and community support in advancing care for people living with HIV.